Selpercatinib Capsules

Seputinib Capsules
Western medicine, prescription medicine, non-medical insurance
This product is used to treat adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with positive rearranged recombinant T2T (RET) gene fusion.
This product is suitable for the treatment of adults and children aged 12 years and above with advanced or metastatic RET mutant medullary thyroid carcinoma (MTC) who require systemic treatment, and for the treatment of adults and children aged 12 years and above with advanced or metastatic RET fusion-positive thyroid cancer who require systemic treatment and are refractory to radioactive iodine (if radioactive iodine is applicable).
The above indications are conditionally approved based on the results of a study of advanced solid tumors with RET gene alterations. Full approval of this indication will depend on clinical benefit from ongoing confirmatory trials.
The anti-tumor drug Selpercatinib has been approved for marketing by the National Medical Products Administration. [1] It is the world’s first approved highly selective RET inhibitor that can inhibit multiple RET mutations. [4] For the treatment of adult patients with RET fusion-positive metastatic non-small cell lung cancer, adult patients and children aged 12 years and older with advanced or metastatic medullary thyroid cancer carrying RET mutations who require systemic therapy, and adult patients and children aged 12 years and older with advanced or metastatic thyroid cancer that is refractory to systemic therapy and radioactive iodine therapy (if applicable).
1. This product is used to treat adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that is positive for rearranged after transfection (RET) gene fusion.
2. This product is indicated for the treatment of adult patients and children aged 12 years and older with advanced or metastatic RET mutant medullary thyroid cancer (MTC) who require systemic therapy, and adult patients and children aged 12 years and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and are refractory to radioactive iodine (if radioactive iodine is applicable).